Japanese firm Ebara and Berlin-based Capsulution NanoScience are now working together to develop a new time-controlled release technology for pharmaceuticals.
In order to achieve this, the two companies will improve the delivery properties of selected concrete active agents using Capsulution's new LBL technology.
The LBL technology (derived from the term "layer-by-layer") is a high-tech tool for making unique multifunctional nano- and micron-sized capsules, which are invisible to the human eye.
Capsulution said that these nano-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties.
In addition, the firm expects that the use of their nanocapsules will show a better performance in evaluating the bioavailability for poorly water-soluble pharmaceuticals.
Therefore, the technology can be used in order to develop tailor-made drug delivery systems, resulting in the development of more effective and convenient therapies for the patient.
The firm claims that this process simplifies the delivery of medications, reduce side effects and increase therapeutic success.
Additional research is aiming for a new effectiveness of the Capsulution nanocapsules that could potentially replace the common progress of multiple medication treatments especially for modern cancer therapy methods.
Capsulution said the new active agents formulas will soon undergo testing to determine their effects on living organisms in the context of pre-clinical experiments in Japan, where the technology is initially being targeted.
"Both partners are convinced that visible results can be achieved in as little as 12 months on the basis of our shared know-how and the increased mutual trust," said Alexander Herrmann, chief financial officer at Capsulution NanoScience.
Capsulution and Ebara have been in collaboration since 2005 when Capsulution designated Ebara as the preferred developer, manufacturer and distributor of its automated "LBL units", however this new alliance will allow Ebera to open up new markets in the field of Life Science with the help of Capsulution's nanotechnology.